Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.